Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers

CYP3A5 genotype is a major determinant of tacrolimus clearance, and has been shown to affect systemic tacrolimus metabolite/parent ratios in healthy volunteers, which may have implications for efficacy and toxicity. In a cohort of 50 renal transplant recipients who underwent quantification of CYP3A4 activity using the oral midazolam drug probe, we confirmed that CYP3A5 genotype is the single most important determinant of tacrolimus metabolite/parent ratio [CYP3A5 expressors displayed 2.7- and 2-fold higher relative exposure to 13-desmethyltacrolimus (DMT) and 31-DMT, respectively; P < 0.001]. There was, however, no relationship between CYP3A4 activity and tacrolimus metabolite/parent ratios. Additional analyses in 16 healthy volunteers showed that dual pharmacological inhibition of CYP3A4 and P-glycoprotein using itraconazole resulted in increased tacrolimus metabolite/parent ratios (+65%, +112%, and 25% for 13-, 15-, and 31-DMT, respectively; P < 0.01). This finding was confirmed in a cohort of nine renal transplant recipients who underwent tacrolimus pharmacokinetic assessments before and during CYP3A4 inhibition (58% increase in overall metabolite/tacrolimus ratio; P = 0.017).

[1]  T. Bouillon,et al.  Fexofenadine, a Putative In Vivo P‐glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients , 2017, Clinical pharmacology and therapeutics.

[2]  D. Lambrechts,et al.  Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype , 2016, The Pharmacogenomics Journal.

[3]  Lydia M. M. Vermeer,et al.  Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters , 2016, Drug Metabolism and Disposition.

[4]  D. Kuypers,et al.  Clinical determinants of calcineurin inhibitor disposition: a mechanistic review , 2016, Drug metabolism reviews.

[5]  D. Kuypers,et al.  Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. , 2013, Pharmacogenomics.

[6]  M. Hebert,et al.  Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition , 2012, Clinical pharmacology and therapeutics.

[7]  K. Verbeke,et al.  In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients , 2012, Clinical pharmacology and therapeutics.

[8]  Russ B Altman,et al.  PharmGKB summary: very important pharmacogene information for CYP3A5. , 2012, Pharmacogenetics and genomics.

[9]  K. Verbeke,et al.  A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. , 2011, Biomedical chromatography : BMC.

[10]  E. Kharasch,et al.  Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam , 2007, Clinical pharmacology and therapeutics.

[11]  G. Cook,et al.  The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation , 2006, Annals of clinical biochemistry.

[12]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[13]  E. Wang,et al.  Interaction of Common Azole Antifungals with P Glycoprotein , 2002, Antimicrobial Agents and Chemotherapy.

[14]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[15]  N. Undre,et al.  The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[16]  U. Christians,et al.  Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. , 1996, Clinical chemistry.

[17]  Paul E. Teschan,et al.  Glomerular filtration rate measurements in clinical trials , 1993 .

[18]  U. Christians,et al.  Additive and synergistic effects of cyclosporine metabolites on glomerular mesangial cells. , 1991, Kidney international.

[19]  J. Thliveris,et al.  Toxicity of Cyclosporine Metabolites , 1990, Therapeutic drug monitoring.

[20]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[21]  S. Uemoto,et al.  Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. , 2008, Drug metabolism and pharmacokinetics.

[22]  K. Iwasaki,et al.  Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[23]  G. Striker.  Modification of diet in renal disease. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.